The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

NuvaRing 0.120 mg/0.015 mg per 24 hours, vaginal delivery system

Organon Pharma (Ireland) LimitedPA23198/020/001

Main Information

Trade NameNuvaRing 0.120 mg/0.015 mg per 24 hours, vaginal delivery system
Active SubstancesEtonogestrel
Dosage FormVaginal delivery system
Licence HolderOrganon Pharma (Ireland) Limited
Licence NumberPA23198/020/001

Group Information

ATC CodeG03BB 5-androstanon (3) derivatives
G03BB01 mesterolone


License statusAuthorised
Licence Issued31/05/2002
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back